Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Arcadia Biosciences stock

RKDA
US0390142042
A2JSFW

Price

2.90
Today +/-
-0.91
Today %
-28.40 %
P

Arcadia Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Arcadia Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Arcadia Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Arcadia Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Arcadia Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Arcadia Biosciences Stock Price History

DateArcadia Biosciences Price
11/15/20242.90 undefined
11/14/20243.86 undefined
11/13/20244.07 undefined
11/12/20244.24 undefined
11/11/20244.24 undefined
11/8/20244.05 undefined
11/7/20244.08 undefined
11/6/20244.16 undefined
11/5/20243.76 undefined
11/4/20243.92 undefined
11/1/20243.84 undefined
10/31/20243.85 undefined
10/30/20244.21 undefined
10/29/20244.25 undefined
10/28/20244.97 undefined
10/25/20244.70 undefined
10/24/20244.31 undefined
10/23/20244.01 undefined
10/22/20243.60 undefined
10/21/20243.46 undefined

Arcadia Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arcadia Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arcadia Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arcadia Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arcadia Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arcadia Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arcadia Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arcadia Biosciences’s growth potential.

Arcadia Biosciences Revenue, EBIT and net profit per share

DateArcadia Biosciences RevenueArcadia Biosciences EBITArcadia Biosciences Net Income
2026e7.65 M undefined-3.84 M undefined-3.11 M undefined
2025e6.66 M undefined-3.59 M undefined-1.78 M undefined
2024e5.36 M undefined-2.89 M undefined-1.95 M undefined
20235.33 M undefined-13.42 M undefined-13.98 M undefined
20229.96 M undefined-16.84 M undefined-15.38 M undefined
20216.78 M undefined-24.09 M undefined-14.66 M undefined
20208.03 M undefined-17.22 M undefined-4.66 M undefined
20191.17 M undefined-19.38 M undefined-28.81 M undefined
20181.46 M undefined-16.87 M undefined-13.48 M undefined
20174.03 M undefined-14.32 M undefined-15.71 M undefined
20163.19 M undefined-18.62 M undefined-19.62 M undefined
20155.41 M undefined-15.56 M undefined-20.73 M undefined
20146.98 M undefined-15.15 M undefined-22.08 M undefined
20136.48 M undefined-10.57 M undefined-13.2 M undefined
20127.01 M undefined-10.13 M undefined-12.37 M undefined

Arcadia Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e
766534118695567
--14.29--16.67-40.0033.33-75.00-700.00-25.0050.00-44.44-20.0016.67
85.7183.3366.6780.0066.6775.00200.00200.0087.5016.6722.2240.0040.0033.3328.57
654423007122000
-12-13-22-20-19-15-13-28-4-14-15-13-1-1-3
-8.3369.23-9.09-5.00-21.05-13.33115.38-85.71250.007.14-13.33-92.31-200.00
0.050.050.050.060.060.050.090.160.250.530.61.24000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Arcadia Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Arcadia Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
5.352.8416.5750.2450.5613.0221.8225.3325.6728.6920.6411.64
0.660.921.420.790.531.240.170.61.411.371.290.51
1001000000000000
0.90.450.420.290.250.230.181.793.814.432.571.96
880260280690880560700710810900900858
7.894.5718.6952.0152.2215.0522.8728.4331.735.3925.414.97
1.130.940.730.590.510.30.43.769.375.372.551.18
2.771.430.519.752.50000000
000000000000
000000003704804039
00000000410000
1.582.64.971.891.351.220.750.375.512.670.933.52
5.484.976.222.234.361.521.154.1315.668.523.524.73
13.379.5424.8974.2456.5816.5724.0232.5647.3643.9128.9219.71
                       
0082.880.040.040.040.050.050.050.060.070.07
76.7578.3329.2172.22173.72175.22191.14214.83239.5257.52278.83284.52
-82.44-95.63-113.97-131.93-151.55-167.26-178.37-207.17-211.83-226.49-257.86-271.84
000-120-20000000101
000000000000
-5.69-17.3-1.8940.2122.19812.827.7127.7231.0921.0412.84
0.140.420.30.440.252.532.680.530.811.480.980.86
1.92.222.9522.14004.84.13.32.962.46
1.322.272.411.010.7410.380.350.270.260.270.27
04.575.61000000000
00.07000000.021.14000
3.369.5511.273.453.133.533.065.76.325.044.213.59
89.928.8724.9325.13000.112.11000
000000000000
7.697.376.645.646.125.048.1618.4310.387.683.813.41
15.6917.2915.5130.5731.255.048.1618.5412.497.683.813.41
19.0526.8426.7834.0234.388.5711.2224.2418.8112.728.027
13.369.5424.8974.2356.5716.5724.0431.9546.5343.8129.0619.84
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Arcadia Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Arcadia Biosciences's financial health and stability.

Assets

Arcadia Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Arcadia Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Arcadia Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Arcadia Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-12-13-18-17-19-15-13-28-6-16-15
0000000001,0000
00000000000
00-1,0000001,0000-12,000-4,0000
334212-112-12-61
00021000000
00000000000
-9-9-14-15-17-13-13-17-30-25-13
0000000-1-2-10
00-1-46-547-5-817161
00-1-46-547-5-619171
00000000000
87-1100-25003-20
00326800242217255
8730680-26222120214
---1.00-9.00--1.00-2.00---1.00-
00000000000
-1-2137-2172-3712-8
-9.88-9.85-14.94-15.26-17.29-14.05-13.88-18.68-32.56-26.88-14.05
00000000000

Arcadia Biosciences stock margins

The Arcadia Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arcadia Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arcadia Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arcadia Biosciences's sales revenue. A higher gross margin percentage indicates that the Arcadia Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arcadia Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arcadia Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arcadia Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arcadia Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arcadia Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arcadia Biosciences Margin History

Arcadia Biosciences Gross marginArcadia Biosciences Profit marginArcadia Biosciences EBIT marginArcadia Biosciences Profit margin
2026e46.42 %-50.17 %-40.62 %
2025e46.42 %-53.9 %-26.67 %
2024e46.42 %-53.92 %-36.38 %
202346.42 %-251.8 %-262.31 %
202226.61 %-169.08 %-154.42 %
202124.63 %-355.31 %-216.22 %
202088.92 %-214.45 %-58.03 %
201923.93 %-1,656.41 %-2,462.39 %
201854.79 %-1,155.48 %-923.29 %
201792.8 %-355.33 %-389.83 %
201671.79 %-583.7 %-615.05 %
201583.55 %-287.62 %-383.18 %
201471.49 %-217.05 %-316.33 %
201389.66 %-163.12 %-203.7 %
201287.02 %-144.51 %-176.46 %

Arcadia Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Arcadia Biosciences earnings per share therefore indicates how much revenue Arcadia Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arcadia Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arcadia Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arcadia Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arcadia Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arcadia Biosciences Revenue, EBIT and net profit per share

DateArcadia Biosciences Sales per ShareArcadia Biosciences EBIT per shareArcadia Biosciences Earnings per Share
2026e5.63 undefined0 undefined-2.28 undefined
2025e4.89 undefined0 undefined-1.31 undefined
2024e3.94 undefined0 undefined-1.43 undefined
20234.31 undefined-10.85 undefined-11.3 undefined
202216.6 undefined-28.07 undefined-25.63 undefined
202112.79 undefined-45.45 undefined-27.66 undefined
202032.12 undefined-68.88 undefined-18.64 undefined
20197.31 undefined-121.13 undefined-180.06 undefined
201816.22 undefined-187.44 undefined-149.78 undefined
201780.6 undefined-286.4 undefined-314.2 undefined
201653.17 undefined-310.33 undefined-327 undefined
201590.17 undefined-259.33 undefined-345.5 undefined
2014139.6 undefined-303 undefined-441.6 undefined
2013129.6 undefined-211.4 undefined-264 undefined
2012140.2 undefined-202.6 undefined-247.4 undefined

Arcadia Biosciences business model

Arcadia Biosciences, Inc. is a California-based company specializing in agricultural biotechnology. The company was founded in 2002 with the goal of improving and making agriculture more sustainable. Arcadia Biosciences focuses on developing plants that are more resistant to external influences such as drought or diseases, resulting in higher yields. In 2003, Arcadia Biosciences entered into a partnership with Monsanto, one of the world's largest producers of pesticides and seeds. This partnership aimed to advance the development of plants that require less pesticides and water, enabling more sustainable agricultural production. In 2008, Arcadia Biosciences acquired seed producer IPFRI, increasing production capacity and accelerating the development of new plant varieties. In 2014, the company went public on the NASDAQ stock exchange under the ticker symbol RKDA. Since then, Arcadia Biosciences has formed additional partnerships and expanded its product range. The company's core business involves developing plant varieties that are resistant to diseases and environmental influences. Arcadia Biosciences utilizes a combination of genetic and conventional breeding methods to modify the genetic makeup of plants, enhancing or weakening certain traits. This approach allows for the development of plants that are less susceptible to pests or heat. As a partner to farmers and food manufacturers, Arcadia Biosciences also provides consulting and training to promote more sustainable agricultural production. Arcadia Biosciences is divided into three business segments: 1. Arcadia Specialty Genomics: This segment specializes in the development of plants with specific traits, such as higher nutrient content or enhanced resistance to diseases. 2. GoodWheat: Under this brand, Arcadia Biosciences sells wheat products that offer a healthier alternative to conventional wheat products due to their ingredients, such as higher fiber or protein content. 3. Hemp: This segment focuses on the development of hemp products, including oil-rich seeds or hemp seeds as superfoods. Arcadia Biosciences offers a variety of products aimed at improving agricultural production and nutrition. Some examples include NitroBoost, a fertilizer that reduces nitrogen loss and improves nutrient uptake in plants; GoodWheat flour, which contains more fiber and protein than conventional wheat flour and is suitable for baking and cooking; ArcaTech, a technology designed to facilitate crop cultivation in areas with limited access to water and nutrients; and hemp seeds, which are rich in essential fatty acids and proteins. In conclusion, Arcadia Biosciences is a company specializing in agricultural biotechnology. Through the development of plants that are resistant to diseases and environmental influences, the company aims to enable more sustainable agricultural production. Arcadia Biosciences has established itself as an important player in the agricultural industry through partnerships and product development. Arcadia Biosciences is one of the most popular companies on Eulerpool.com.

Arcadia Biosciences SWOT Analysis

Strengths

One of the key strengths of Arcadia Biosciences Inc is its advanced biotechnology capabilities. The company has developed innovative technologies that contribute to crop improvement and sustainability.

Arcadia Biosciences Inc has a strong intellectual property portfolio, which includes patents and proprietary technologies. This gives the company a competitive advantage and provides a solid foundation for future growth.

The company has a well-established network of partnerships with leading agricultural companies, enabling it to access additional resources and expand its market reach.

Arcadia Biosciences Inc has a dedicated and experienced team of professionals who are experts in their respective fields. This expertise allows the company to stay at the forefront of biotechnology innovation.

Weaknesses

One of the weaknesses of Arcadia Biosciences Inc is its limited financial resources. The company may face challenges in funding its research and development activities or expanding its operations.

Arcadia Biosciences Inc operates in a highly regulated industry, which can slow down the pace of product development and commercialization. This could potentially hinder the company's growth opportunities.

Opportunities

The increasing global demand for agricultural products presents significant growth opportunities for Arcadia Biosciences Inc. The company can leverage its technologies to develop crops with improved yield, nutritional value, and resistance to pests and diseases.

Expanding into emerging markets, such as Asia and Latin America, could provide Arcadia Biosciences Inc with new customer bases and revenue streams.

Growing consumer awareness and demand for sustainable and eco-friendly practices create a favorable market environment for Arcadia Biosciences Inc's products.

Threats

Arcadia Biosciences Inc operates in a highly competitive industry, with other biotechnology companies and large agricultural corporations vying for market share. This intensifies the pressure to consistently innovate and differentiate.

Changes in government regulations and policies related to genetically modified crops and biotechnology could pose threats to the company's operations and commercialization efforts.

Unforeseen environmental factors, such as climate change and natural disasters, can impact crop production and disrupt supply chains, affecting Arcadia Biosciences Inc's business.

Arcadia Biosciences Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Arcadia Biosciences Revenue by Segment

Segmente20222021202020192018
Product-6.59 M USD1.04 M USD814,000 USD657,000 USD
Product Revenues8.96 M USD----
License-17,000 USD6.8 M USD67,000 USD150,000 USD
Contract research and government grants--106,000 USD288,000 USD657,000 USD
License Revenues879,000 USD----
Royalty117,000 USD176,000 USD83,000 USD--

Arcadia Biosciences Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Arcadia Biosciences Revenue by Segment

DateAfricaArgentinaARGENTINAAustriaCanadaCANADAGermanyIndiaINDIASpainUnited KingdomUnited States
2022-862,000 USD--194,000 USD-57,000 USD7,000 USD---8.84 M USD
2021--26,000 USD--503,000 USD--7,000 USD225,000 USD16,000 USD6 M USD
2020106,000 USD6.68 M USD-32,000 USD354,000 USD--100,000 USD---761,000 USD
2019182,000 USD---258,000 USD--7,000 USD---722,000 USD
2018115,000 USD---91,000 USD--90,000 USD---1.17 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Arcadia Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Arcadia Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Arcadia Biosciences shares outstanding

The number of shares was Arcadia Biosciences in 2023 — This indicates how many shares 1.237 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arcadia Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arcadia Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arcadia Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arcadia Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arcadia Biosciences stock splits

In Arcadia Biosciences's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Arcadia Biosciences.

Arcadia Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20241.58 0.78  (-50.66 %)2024 Q2
3/31/2024-2.26 -1.78  (21.21 %)2024 Q1
12/31/2023-2.64 -2.52  (4.43 %)2023 Q4
9/30/2023-3.25 -1.44  (55.74 %)2023 Q3
6/30/2023-4.9 -2.65  (45.87 %)2023 Q2
3/31/2023-6.99 -10.86  (-55.43 %)2023 Q1
12/31/2022-6.94 -6.29  (9.31 %)2022 Q4
9/30/2022-8.57 -4.8  (43.98 %)2022 Q3
6/30/2022-12.24 -8  (34.64 %)2022 Q2
3/31/2022-13.87 -8  (42.33 %)2022 Q1
1
2
3
4

Arcadia Biosciences shareholders

%
Name
Stocks
Change
Date
2.06941 % Moral Compass Corporation28,14401/20/2023
1.03221 % The Vanguard Group, Inc.14,03806/30/2024
0.89309 % State Street Global Advisors (US)12,14606/30/2024
0.60316 % Geode Capital Management, L.L.C.8,203-1158/31/2024
0.36765 % Jacot (Stanley Jr)5,0005,0005/1/2024
0.14566 % Kawakami (Mark)1,9817008/1/2024
0.13110 % Tower Research Capital LLC1,783-1,9916/30/2024
0.10434 % Schaefer (Thomas J.)1,4197008/1/2024
0.04456 % Morgan Stanley & Co. LLC6064006/30/2024
0.03676 % Comcowich (Kevin J.)50005/1/2024
1
2
3
4
...
5

Arcadia Biosciences Executives and Management Board

Mr. Stanley Jacot(53)
Arcadia Biosciences President, Chief Executive Officer, Director (since 2022)
Compensation 749,467
Ms. Laura Pitlik(49)
Arcadia Biosciences Chief Marketing Officer
Compensation 452,915
Mr. Kevin Comcowich(54)
Arcadia Biosciences Independent Chairman of the Board (since 2016)
Compensation 312,169
Mr. Gregory Waller(73)
Arcadia Biosciences Independent Director
Compensation 94,000
Ms. Lilian Murray(64)
Arcadia Biosciences Independent Director
Compensation 89,500
1
2

Arcadia Biosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bioceres Crop Stock
Bioceres Crop
SupplierCustomer0,810,700,350,390,20-0,65
E2open Parent Holdings A Stock
E2open Parent Holdings A
SupplierCustomer0,640,120,700,090,630,30
Corteva Stock
Corteva
SupplierCustomer0,630,680,160,46-0,58-0,72
1

Most common questions regarding Arcadia Biosciences

What values and corporate philosophy does Arcadia Biosciences represent?

Arcadia Biosciences Inc represents a commitment to sustainable agriculture and addressing global food challenges. With a focus on science-based innovation, the company aims to improve crop productivity, nutritional content, and resource efficiency. Arcadia Biosciences Inc's corporate philosophy revolves around providing safe and healthy food options for consumers while reducing the environmental impact of agriculture. By harnessing advanced breeding techniques and genetic improvement, Arcadia Biosciences Inc strives to create crops that are resilient, high-yielding, and able to thrive in diverse environments. This emphasis on innovation and sustainability underscores Arcadia Biosciences Inc's dedication to shaping the future of agriculture.

In which countries and regions is Arcadia Biosciences primarily present?

Arcadia Biosciences Inc primarily operates in the United States.

What significant milestones has the company Arcadia Biosciences achieved?

Arcadia Biosciences Inc has achieved several significant milestones. The company successfully developed its flagship product, GoodWheat™, which offers healthier wheat with enhanced nutritional profiles. Additionally, Arcadia Biosciences Inc obtained regulatory approvals for its products, including GoodWheat™ high fiber and reduced gluten varieties. The company also forged partnerships with prominent agricultural players to expand its market reach. Moreover, Arcadia Biosciences Inc received industry recognition through awards like the Institute for Innovations in Agriculture's Excellence in Ag Science Award. These milestones highlight the company's commitment to developing innovative and sustainable solutions in the agricultural industry.

What is the history and background of the company Arcadia Biosciences?

Arcadia Biosciences Inc is an agricultural biotechnology company based in Davis, California. Founded in 2002, Arcadia Biosciences focuses on developing and commercializing innovative traits and products to enhance crop productivity and quality. The company aims to address global agricultural challenges such as crop yield improvement, nutritional enhancement, and the sustainability of farming practices. With a strong focus on genetic engineering and advanced breeding techniques, Arcadia Biosciences has developed several breakthrough technologies and collaborations that have paved the way for sustainable agriculture. Through its research and development, Arcadia Biosciences strives to create value for farmers, consumers, and the environment.

Who are the main competitors of Arcadia Biosciences in the market?

The main competitors of Arcadia Biosciences Inc in the market include companies such as Monsanto Company, Syngenta AG, Bayer CropScience AG, and DowDuPont Inc. These companies operate in the agricultural biotechnology industry, focusing on genetic modification, crop protection, and seed development. Arcadia Biosciences Inc competes by offering innovative solutions and technologies, including its proprietary trait development platform, enabling higher crop yields, improved nutritional profiles, and environmental sustainability. With its diverse portfolio and commitment to addressing global agricultural challenges, Arcadia Biosciences Inc strives to stand out in a competitive marketplace.

In which industries is Arcadia Biosciences primarily active?

Arcadia Biosciences Inc is primarily active in the agricultural biotechnology industry.

What is the business model of Arcadia Biosciences?

Arcadia Biosciences Inc. is a biotechnology company specializing in developing and commercializing agricultural products to improve crop quality and productivity. They utilize advanced breeding techniques, including genetic modification and gene editing, to enhance desirable traits in important crops. Arcadia Biosciences focuses on traits such as drought tolerance, nitrogen use efficiency, and disease resistance to address the challenges faced by farmers and enhance sustainability in agriculture. By leveraging their expertise in biotechnology, Arcadia Biosciences aims to create innovative solutions that benefit both farmers and consumers, ensuring a more secure and sustainable food supply.

What is the P/E ratio of Arcadia Biosciences 2024?

The Arcadia Biosciences P/E ratio is -1.84.

What is the P/S ratio of Arcadia Biosciences 2024?

The Arcadia Biosciences P/S ratio is 0.67.

What is the Quality Investing of Arcadia Biosciences?

The Quality Investing for Arcadia Biosciences is 2/10.

What is the revenue of Arcadia Biosciences 2024?

The expected Arcadia Biosciences revenue is 5.36 M USD.

How high is the profit of Arcadia Biosciences 2024?

The expected Arcadia Biosciences profit is -1.95 M USD.

What is the business model of Arcadia Biosciences

Arcadia Biosciences Inc is a company specializing in the development and marketing of high-quality agricultural products. It is based in California, USA. The company is a leader in the development of agricultural biotechnology solutions that improve crop cultivation while protecting the environment. Its business model includes various sectors, including product development, marketing, and distribution.

What is the Arcadia Biosciences dividend?

Arcadia Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Arcadia Biosciences pay dividends?

The dividend cannot currently be calculated for Arcadia Biosciences or the company does not pay out a dividend.

What is the Arcadia Biosciences ISIN?

The ISIN of Arcadia Biosciences is US0390142042.

What is the Arcadia Biosciences WKN?

The WKN of Arcadia Biosciences is A2JSFW.

What is the Arcadia Biosciences ticker?

The ticker of Arcadia Biosciences is RKDA.

How much dividend does Arcadia Biosciences pay?

Over the past 12 months, Arcadia Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arcadia Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Arcadia Biosciences?

The current dividend yield of Arcadia Biosciences is .

When does Arcadia Biosciences pay dividends?

Arcadia Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arcadia Biosciences?

Arcadia Biosciences paid dividends every year for the past 0 years.

What is the dividend of Arcadia Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arcadia Biosciences located?

Arcadia Biosciences is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Arcadia Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arcadia Biosciences from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Arcadia Biosciences pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Arcadia Biosciences in the year 2023?

In the year 2023, Arcadia Biosciences distributed 0 USD as dividends.

In which currency does Arcadia Biosciences pay out the dividend?

The dividends of Arcadia Biosciences are distributed in USD.

All fundamentals about Arcadia Biosciences

Our stock analysis for Arcadia Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arcadia Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.